B. Braun Partners with Cognite to Power Its Data-First Transformation
17.1.2023 10:00:00 EET | Business Wire | Press release
Cognite, a global leader in industrial software, today announced B. Braun, a leading medical technology company, has selected Cognite Data Fusion® as the core of its Manufacturing Data Management solution. By integrating Cognite’s Industrial DataOps platform with its manufacturing domain knowledge, B. Braun leverages digital twins and AI-powered applications to achieve operational excellence across production, maintenance, and sustainability.
The Manufacturing Data Management solution will provide a fully digital DevOps workflow to develop, deploy, and sustain a pipeline of business applications. Cognite Data Fusion® will integrate and contextualize all operational data from product development, engineering, production, quality management, maintenance, EHS, and enterprise systems into one contextualized data layer that adheres to and extends industry standards for data modeling and enables the evolution of those data models over time as needed. The Manufacturing Data Management solution will provide comprehensive, easily accessible, and trusted information to both domain experts and developers, creating the foundation for data-driven transformation at scale.
Abram Ziegelaar, VP of Operational Technology at B. Braun Medical Industries in Malaysia, highlights three main value drivers of the solution:
"First, our wide variety of front-line workers and domain experts can collaborate with a common pool of trusted, real-world, live data from diverse sources and integrated, standardized applications. They get the information they need with the business context they need to respond quickly. This provides significant efficiency gains and reduces errors caused by poor quality or inaccessible information and disjointed processes.
" Second, our front-line people often intuitively know what needs to be done to improve performance, but lack the tools to test their intuition. Controlled access to a rich universe of well-curated information turns our front-liners into 'citizen data scientists' who can own their reports and analyses, make better decisions, and demonstrate the viability of improvement possibilities with real data. After implementation, we can measure the actual effects of improvements. Doing all of this in a global platform across many sites allows us to rapidly spread this knowledge and multiply the gains. 'Continuous Improvement' really becomes continuous.
" Third, you don't know what you don't know. A unique value of Cognite Data Fusion's AI-powered data contextualization is how it provides us with the 'smarts’ to answer very complex questions and create visibility into new areas to explore."
"On behalf of Cognite, we are proud to partner with B. Braun as they transform into a data-first organization based on a strong operational data foundation. Cognite Data Fusion®, which provides simple access to complex industrial data, will fast track time to value of the Manufacturing Data Management solution and empower B. Braun to build and scale valuable business solutions," said Petteri Vainikka, Chief Marketing Officer at Cognite.
As part of the partnership, Cognite will collaborate with B. Braun to integrate its in-house support tools with Cognite’s user community, Cognite Hub, to provide seamless support to the B. Braun organization. To learn more about Cognite Data Fusion, visit: cognite.com/en/product/cognite_data_fusion_industrial_dataops_platform
About B. Braun
As one of the world's leading medical technology companies, B. Braun protects and improves the health of people around the world. For over 180 years, the family-owned company has been accelerating progress in health care with pioneering spirit and groundbreaking contributions. This innovative strength continues to be the foundation of B. Braun's success today—always with the goal of improving clinical outcomes, cost of care, and patient benefits.
More than 66,000 employees live Sharing Expertise worldwide, they make B. Braun a true partner that develops smart solutions and sets new standards. By linking products, services, and consulting, the company improves treatment processes and supports medical staff. In doing so, B. Braun always acts with future generations in mind, which is why responsibility for sustainable growth is embedded into all business processes. In 2021, the B. Braun Group generated sales of € 7.9 billion. Visit us at www.bbraun.com.
About Cognite
Cognite is a global industrial SaaS company that was established with a clear vision: to rapidly empower industrial companies with open, contextualized, trustworthy, and accessible data to help drive the full-scale digital transformation of asset-intensive industries around the world. Our core Industrial DataOps platform, Cognite Data Fusion®, enables industrial data and domain users to collaborate quickly and safely to develop, operationalize, and scale industrial AI solutions and applications to deliver both profitability and sustainability. Visit us at www.cognite.com and follow us on Twitter and LinkedIn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230116005369/en/
Contact information
Michelle Holford, Vice President of Global Public Relations
michelle.holford@cognite.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Samsung Bioepis Announces Positive Preliminary Phase 1 Data for SB27, Proposed Biosimilar to Keytruda (Pembrolizumab)6.5.2026 02:00:00 EEST | Press release
Samsung Bioepis Co., Ltd. announced today that the Phase 1 study on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), has met its primary pharmacokinetics (PK) endpoints. The randomized, double-blind, three-arm, parallel group, multicenter clinical trial demonstrated pharmacokinetic bioequivalence of SB27 (pembrolizumab) to the reference product Keytruda. Initiated in January 2024, Phase 1 study is being conducted in four countries, and is expected to be completed by November 2026.2 The study assessed pharmacokinetics, efficacy, safety, and immunogenicity of SB27, EU-sourced Keytruda, and US-sourced Keytruda in patients with stage II or IIIA non-small cell lung cancer (NSCLC) following complete resection and adjuvant platinum-based chemotherapy. 163 participants were randomized to receive SB27, EU-sourced Keytruda, or US-sourced Keytruda every 3 weeks, maximum 18 cycles over about 51 weeks, and blood samples were collected. The preliminary pharmacokinetic evaluation indicates t
Megaport Launches Built-In DDoS Protection Enabling On-Demand Network Resilience6.5.2026 01:00:00 EEST | Press release
Megaport Limited (ASX: MP1) (“Megaport”), a leading global automated infrastructure platform, today announced the launch of Megaport DDoS Protection. This new, built-in security capability for Megaport Internet allows customers to filter malicious traffic directly within the Megaport network rather than routing it through a separate or external service, for mission-critical uptime without introducing additional latency or routing complexity. As enterprises increasingly migrate to distributed cloud environments, traditional DDoS mitigation has struggled to keep pace with cloud and distributed infrastructure adoption. Standard ISP solutions often resort to dropping all traffic and taking the service offline to protect the network, while external third-party providers force a "security detour" that reroutes traffic through public infrastructure, introducing significant latency and complexity. Megaport DDoS Protection removes these challenges by integrating fabric-native protection directl
IFF Reports First Quarter 2026 Results5.5.2026 23:23:00 EEST | Press release
IFF (NYSE: IFF) reported financial results for the first quarter ended March 31, 2026. First Quarter 2026 Consolidated Summary: Management Commentary “IFF is off to a solid start in 2026, with first quarter results that reflect the customer focus and operational execution we’ve been building across the company,” said Erik Fyrwald, CEO of IFF. “We delivered volume growth in all four segments, improved profitability, and generated strong cash flow in the first quarter. As we look ahead, we are maintaining a disciplined approach to how we are planning the balance of the year as the current operating environment remains unsettled. We remained focused on advancing our commercial and innovation pipelines, driving productivity, and working with customers to offset inflation. This – when combined with our solid start to the year – derisks the balance of the year and gives us the confidence to reaffirm our full-year 2026 financial guidance ranges in an uncertain environment. At the same time, w
Logitech Announces Q4 and Full Fiscal Year 2026 Results5.5.2026 23:06:00 EEST | Press release
SIX Swiss Exchange Ad hoc announcement pursuant to Art. 53 LR — Logitech International (SIX: LOGN) (Nasdaq: LOGI) today announced financial results for the fourth quarter and full Fiscal Year 2026. For Fiscal Year 2026: Sales were $4.84 billion, up 6 percent in US dollars and 4 percent in constant currency compared to the prior year. GAAP operating income was $775 million, up 18 percent compared to the prior year. Non-GAAP operating income was $911 million, up 18 percent compared to the prior year. GAAP earnings per share was $4.80, up 16 percent compared to the prior year. Non-GAAP EPS was $5.78, up 19 percent compared to the prior year. Cash flow from operations was $1.04 billion. The year-ending cash balance was $1.7 billion. The Company returned $768 million of cash to shareholders through its annual dividend payment and share repurchases. For Q4 Fiscal Year 2026: Sales were $1.09 billion, up 7 percent in US dollars and 3 percent in constant currency compared to Q4 of the prior yea
Sentinel Midstream Advances Texas GulfLink Deepwater Port5.5.2026 23:00:00 EEST | Press release
Sentinel Midstream LLC (Sentinel) today announced the commencement of its Texas GulfLink deepwater port (Texas GulfLink or the Project), marking a significant milestone enabled by funding received pursuant to the U.S.—Japan Trade Agreement. The project advances in coordination with the U.S. Department of Commerce and the Government of Japan and reflects the shared commitment to strengthening global energy security and expanding U.S. export infrastructure. Sentinel will lead the development of Texas GulfLink, overseeing construction, commercial operations, and long-term management of the terminal. Funding provided under the U.S.—Japan Trade Agreement, pursuant to Executive Order 14345 signed on September 4, 2025, underscores continued international confidence in U.S. energy infrastructure and supports the expansion of American crude oil exports to global markets. Upon this commencement, Texas GulfLink will immediately begin construction of its deepwater crude oil export terminal, unlock
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom